Ad hoc releases are announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
View Featured news and Pulse updates.
Ad hoc releases are announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
View Featured news and Pulse updates.
Collaborations are driving advances in sickle cell disease research, bringing new hope to patients.
Working with a nonprofit, Novartis is helping train healthcare workers to diagnose and treat chronic ailments such as diabetes.
Novartis is strongly committed in helping and supporting employees impacted by cancer through the program Ensemble – Caring for Colleagues (Ensemble).
At Novartis, we celebrate life and recognize moments that matter. Michael Wieser shares his experience of parental leave and becoming a father of two.
Novartis immunologist describes the excitement of discovering a promising new immuno-oncology (IO) target in the treatment of acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
Caring for a baby with retinopathy of prematurity (ROP) has never been easy. But mother and social visionary Silke Mader has made it her life’s work to ensure that parents dealing with ROP and other complications today get more support than she did.
Advanced Accelerator Applications is working on marrying targeted drug design with nuclear medicine technology to develop drugs that can recognize and treat diseases.
For all too many people living with heart failure, hospitalizations are a recurring part of life, affecting the lives of both patients and their caregivers.
A collaboration in Ghana aims to expand early diagnosis and treatment of people with this inherited illness.
Novartis researchers are learning how a novel approach to immunotherapy could help treat cancer.